VYNE Therapeutics reports Q4 EPS (20c) vs. ($2.60) last year

Reports Q4 revenue $76,000 vs. $6,000 last year. “We have entered 2024 with positive momentum, following an exciting year highlighted by our clinical proof-of-concept data for VYN201 and a successful financing with leading healthcare institutional investors,” said David Domzalski, President and CEO of VYNE. “We have made excellent progress with our VYN201 program and remain on track to initiate a Phase 2b trial in nonsegmental vitiligo next quarter. In addition, we expect to submit supplemental nonclinical information to the FDA in the coming weeks in support of our IND for VYN202, and assuming clearance by the FDA, we expect to commence our Phase 1a SAD/MAD trial next quarter as well. We look forward to providing updates on our programs over the coming months.”